Literature DB >> 28737580

Nivolumab-Induced Development of Pulmonary Sarcoidosis in Renal Cell Carcinoma.

Meng Zhang1, Geoffrey Schembri.   

Abstract

A 64-year-old woman with metastatic clear cell renal carcinoma who had been on nivolumab immunotherapy for 10 months was referred for a FDG PET scan to monitor disease progress. New bilateral mediastinal and hilar FDG-avid lymphadenopathy was noted. Pathology on subsequent mediastinal nodal biopsy showed well-formed epithelioid granulomas with no evidence of malignancy consistent with sarcoidosis. This case illustrates that pulmonary sarcoidosis can be induced by immunotherapy in the treatment of renal cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28737580     DOI: 10.1097/RLU.0000000000001758

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  7 in total

1.  Diagnostic impact of 18F-FDG PET/CT imaging on the detection of immune-related adverse events in patients treated with immunotherapy.

Authors:  Gamze Tatar; Göksel Alçin; Nilay Sengul Samanci; Özge Erol Fenercioglu; Ediz Beyhan; Tevfik Fikret Cermik
Journal:  Clin Transl Oncol       Date:  2022-05-20       Impact factor: 3.340

2.  Suspected immune checkpoint inhibitor-induced pulmonary sarcoid reaction in metastatic renal cell carcinoma.

Authors:  Victoria Purcell; Beatrice Preti; Ricardo Fernandes
Journal:  Clin Case Rep       Date:  2022-07-11

Review 3.  FDG PET/CT for Assessment of Immune Therapy: Opportunities and Understanding Pitfalls.

Authors:  Steve Y Cho; Daniel T Huff; Robert Jeraj; Mark R Albertini
Journal:  Semin Nucl Med       Date:  2020-06-28       Impact factor: 4.446

Review 4.  Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature.

Authors:  Devis Benfaremo; Lucia Manfredi; Michele Maria Luchetti; Armando Gabrielli
Journal:  Curr Drug Saf       Date:  2018

5.  Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy.

Authors:  Noha Abdel-Wahab; Maria E Suarez-Almazor
Journal:  Rheumatology (Oxford)       Date:  2019-12-01       Impact factor: 7.580

6.  Case Report: Hepatic Sarcoid-Like Reaction Associated With Checkpoint Inhibition in a NSCLC Patient and a Literature Review.

Authors:  Yuxin Lin; Wei Zhu; Bingchen Wu; Huiyin Lan
Journal:  Front Oncol       Date:  2022-03-10       Impact factor: 6.244

7.  Pulmonary Sarcoidosis Activation following Neoadjuvant Pembrolizumab plus Chemotherapy Combination Therapy in a Patient with Non-Small Cell Lung Cancer: A Case Report.

Authors:  Ghina Fakhri; Reem Akel; Ziad Salem; Ayman Tawil; Arafat Tfayli
Journal:  Case Rep Oncol       Date:  2017-11-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.